This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Sage Therapeutics’s 8K filing here.
Sage Therapeutics Company Profile
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
Recommended Stories
- Five stocks we like better than Sage Therapeutics
- Best Stocks Under $5.00
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- The Basics of Support and Resistance
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Hot Stock Trends to Ride Into 2025
